PPARA and type 2 diabetes mellitus: In addition to reduced triglyceride concentrations, our findings indicate that adding PPARα/γ activator (tesaglitazar) to metformin treatment does not significantly affect the concentrations of TC and LDL-C as compared to the patients with type 2 diabetes who were treated with metformin only.